Evotec signs up for a 5-year dis­cov­ery deal with Bay­er fo­cused on chron­ic kid­ney dis­ease

Four years af­ter Evotec first signed on to col­lab­o­rate with Bay­er on new ther­a­pies for en­dometrio­sis, the part­ners have de­cid­ed to add a new dis­cov­ery ef­fort fo­cused on chron­ic kid­ney dis­ease.

Un­der the agree­ment, in­ves­ti­ga­tors at both com­pa­nies will get a chance to con­tribute tar­gets to the re­search ef­fort. Evotec gets a guar­an­tee of at least 14 mil­lion eu­ros over the 5-year stretch of the col­lab­o­ra­tion. And there’s a chance to earn an­oth­er $300 mil­lion eu­ros in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.